Objective To explore the effect of docetaxel,cisplatin combined with concurrent chemotherapy and radiotherapy in the treatment of patients with advanced cervical cancer.Methods 64 patients with advanced cervical cancer were randomly divided into two groups,observation group with 32 cases who were treated with docetaxel and cisplatin concurrent chemotherapy and radiotherapy and control group with 32 cases were treated with radiotherapy.The clinical effect and adverse reaction between two groups were compared.Results The total effective rate in observation group was 84.4％,which significantly higher than that in control group of 59.4％ ( x2 =4.07,P ＜0.05 ).There were no significant differences in incidences of bone marrow suppression and nausea and vomiting between two groups(x2 =1.09,1.17,all P ＞0.05).Conclusion Docetaxel,cisplatin combined with concurrent chemotherapy and radiotherapy in the treatment of patients with advanced cervical cancer could enhance clinical effect,and not increase the adverse reaction incidence,which could be applied in clinic.

Objective To explore the expression and clinical significance of peroxisome proliferator-activated receptor gamma (PPAR γ) in breast tissue in obese patients with breast cancer.Methods Breast tissue samples were collected from 60 obese patients with breast cancer (obese group),60 normal weight patients with breast cancer (normal weight group),the expression of PPAR γmRNA and protein of breast tissue were detected by reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemistry in all patients,and the data was analyzed between PPARγ mRNA and protein.Results Compared with normal weight group,the expression of PPAR γ mRNA and protein of breast tissue in obese group were increased obviously(0.79 ± 0.06 vs 0.42 ± 0.04,0.55 ± 0.07 vs 0.23 ± 0.03 )(P＜ 0.05 ),while the expression of PPAR 3 mRNA and protein were positively correlated (r =0.81,P＜ 0.05 ).In obese group,the positive expression of PPAR γ was 47 cases with 10 cases (21.3％) recurrence and metastasis,the negative expression of PPAR 3 was 13 cases with 11 cases (84.6％) recurrence and metastaais,there was significant difference(P ＜ 0.05 ).In normal weight group,the positive expression of PPAR γwas 19 cases with 4 cases ( 21.1％ ) recurrence and metastasis,the negative expression of PPAR 3 was 41 cases with 10 cases (24.4％) recurrence and metastasis,there was no significant difference (P ＞ 0.05 ).Conclusions Obese patients with breast cancer own a high expression trend of expression of PPAR γ mRNA and protein of breast tissue,which indicates that PPARγ may be play an important role in occurrence,evolvement and prognosis of obesity-related breast cancer.

Objective To observe the efficacy and side effects of exemestane in postmenopausal breast cancer patients with bone metastasis.Methods One hundred and ten postmenopausal breast cancer patients with bone metastasis were treated with exemestane 25 mg.Results In the evaluable data from 110 patients,the complete remission(CR)was encountered in 7 cases,partial remission(PR)in 28 cases,with a total response rate of 31.8％ ;Thirty nine patients had stabled diseases for more than 24 weeks.It produced a clinical benefit (CR + PR + SD)over 24 weeks in 74 cases(67.3％).Diseases progressed in 12 of the cases(10.9％).The patients with positive ER and PR status had a higher chance to be benefited from the treatment than those with negative receptor status.The clinical efficacy was not correlated with treatment history,pathological subtypes and bone,liver,lung and lymph node metastasis(x2 =0.045,0.078,0.200,P ＞ 0.05).No severe adverse effects were observed.Conclusion Exemestane is effective to treat bone metastasis of breast cancer with minor adverse reactions and good tolerability.